You are here

FSD Pharma Inc. Subordinate Voting Shares

Listing Exchange: 
CSE
Status: 
Active
Industry: 
Life Sciences
Symbol: 
HUGE
CSE Index: 
Currency: 

FSD Pharma, Inc., is a publicly traded holding company since May 2018.

FSD BioSciences, Inc., a wholly-owned subsidiary, is a specialty biotech pharmaceutical R&D company focused on developing over time multiple applications of its lead compound, FSD201, ultra-micronized palmitoylethanolamide (PEA). Ultra-micro PEA is known to target the CB2 receptors of the endocannabinoid system of the human body and acts by down-regulating the pro-inflammatory cytokines to effectuate an anti-inflammatory response.

The company has successfully completed Phase 1 first-in-human safety and tolerability study for FSD201 and has found the compound to be safe with no serious adverse side effects. This study also validated considerable scientific literature already published in the European Union that claims safety and tolerability of micro-PEA. Ultra-micro PEA is currently beings dispensed in Italy and Spain as a prescription based medical food supplement since 2004.

The company received permission from the Food and Drug Administration (FDA) on June 1, 2020 to submit an Investigational New Drug Application (IND) for the use of FSD201 to treat COVID-19, the disease caused by the SARS-CoV-2 virus.

Severe COVID-19 is characterized by an over-exuberant inflammatory response that may lead to a cytokine storm and ultimately death. The Company is focused on developing FSD201 for its anti-inflammatory properties to avoid the cytokine storm associated with acute lung injury in hospitalized COVID-19 patients.

 

You are here

FSD Pharma Inc. Subordinate Voting Shares (HUGE)

SEDAR Information

Company Info

Address
First Canadian Place
100 King St. West, Suite 3400
Toronto, ON M5X 1A4
Canada
Phone
(289) 677-0806
Fax
(905) 373-0303
Email
info@fsdpharma.com
Website
https://www.fsdpharma.com
Listing date
Tuesday, May 29, 2018
Transfer Agent
Computershare Investor Services Inc.
Investor Relations
Sandra Huard
Email
sandy@fsdpharma.com
Auditor
MNP LLP

Advertisement

Publicité

Capitalization

Issued & Outstanding: 
14,722,698
Reserved for Issuance: 
3,439,074

Company Officers

Dr. Raza Bokhari, Chief Executive Officer and Co-Chairman - FSD Pharma Inc.
Anthony Durkacz, Co-Chairman - FSD Pharma Inc.
Zeeshan Saeed, President - FSD Pharma Inc.
Donal Carroll, Chief Financial Officer

Bulletins

11/10/2019

2019-1006 – Consolidation - FSD Pharma Inc. Subordinate Voting Shares (HUGE)

le 11 octobre/October 2019

FSD Pharma Inc. has announced a consolidation of its Class B Subordinate Voting shares on the basis  of one (1) post-consolidation common share for every two hundred one (201) pre-consolidation common shares.

As a result, the outstanding shares of the company will be reduced to approximately 7,874,809.

The shares will begin trading on a consolidated basis and with a new CUSIP number on October 16, 2019.

The name and symbol will not change.

Advertisement

Publicité

Latest CSE News

Upcoming Events

image_2.png

The Impact of the Pandemic on Women's Advancement during Recovery

Tuesday, September 29, 2020 -
12:00pm to 1:00pm
2020-09-29-Tech-Tuesdays-Best-of-Summer_Website.jpg

Tech Tuesdays

Tuesday, September 29, 2020 -
4:15pm to 5:00pm
2020-09-30-The-Psychedelics-Renaissance_Website.png

The Psychedelics Renaissance

Wednesday, September 30, 2020 -
1:00pm to 3:00pm